AccessibilityHelpAbout Us
Avicanna logo

Avicanna(TSX) AVCN

Market CapCA$14.78MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-98%
5 Year-89%
1 Year-59%
1 Month-19%
CA$0.11
-4.55%
-0.00Today
Avicanna last closing stock price
MetricPriceDate
Last closeCAD 0.112026-09-18
Avicanna stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.55%CAD 0.112026-09-11
1 month-19.23%CAD 0.132026-08-19
3 month-19.23%CAD 0.132026-06-19
Year to date-53.33%CAD 0.232025-12-30
1 year-58.82%CAD 0.262025-09-18
3 year-77.66%CAD 0.472023-09-19
5 year-88.71%CAD 0.932021-09-17
Since inception-98.23%CAD 6.232019-07-18

Avicanna Financials at a Glance

Market Cap

CA$14.78MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$25.31M

Net Income (TTM)

-CA$3.91M

EPS (TTM)

-CA$0.03

P/E Ratio

-3.38

Dividend

CA$0.00

Beta (Volatility)

1.04 (Average)

Price

CA$0.11

Volume

91,000

Open

CA$0.11

Previous Close

CA$0.11

Daily Range

CA$0.11 - CA$0.11

52-Week Range

CA$0.10 - CA$0.30

Estimated Earnings Date

Nov 13, 2026

AVCN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Avicanna

Avicanna Inc. is a biopharmaceutical company based in Toronto, Canada, focused on the research, development, and commercialization of scientifically validated cannabinoid-based products for medical and consumer health markets. Founded in 2016, the company has established a comprehensive scientific framework that includes R&D and clinical trials, often in collaboration with academic and medical institutions.

Products and Services
  • Medical and wellness products under the RHO Phyto brand
  • CBD-infused topical and derma-cosmetic products under Pura H&W and Pura Earth
  • Bulk cannabis and hemp-derived raw materials through the Aureus brand
Growth Outlook
  • Partnerships with academic institutions enhance product development capabilities
  • Expansion into global markets is underway, targeting diverse consumer segments
  • Focus on cannabinoid-based therapies for chronic conditions presents significant opportunities
Financial Highlights
  • Q2 2026 revenue of CAD 5.64 million, showing a strong market presence
  • Trailing twelve months (TTM) gross profit margin at 51.87%, indicating effective cost management
  • Current ratio of 0.97 suggests adequate short-term financial health
Avicanna Inc. is positioned in a rapidly evolving industry, leveraging scientific research to develop innovative products. The company's diverse product offerings and strategic partnerships with academic institutions enhance its potential for growth. Recent financial performance indicates a solid revenue stream and effective cost management, which may appeal to investors looking for opportunities in the biopharmaceutical sector. The focus on cannabinoid-based therapies for chronic conditions further underscores the company's commitment to addressing significant health challenges, potentially leading to long-term value creation.
AI Generated • Sep 15, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

112

CEO

Aras Azadian, MBA

Website

www.avicanna.com

Headquarters

Toronto, ON M5G 1V2, CA

AVCN Financials

Key Financial Metrics (TTM)

Gross Margin

51.87%

Operating Margin

-14.76%

Net Income Margin

-15.45%

Return on Equity

-108.44%

Return on Capital

-95.51%

Return on Assets

-16.21%

Earnings Yield

-29.59%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

CA$14.78MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

134.38M

Volume

91.00K

Avg. Volume

128.06K

Financials (TTM)

Gross Profit

CA$13.13M

Operating Income

-CA$3.74M

EBITDA

-CA$3.04M

Operating Cash Flow

-CA$3.15M

Capital Expenditure

-CA$206.87K

Free Cash Flow

-CA$3.36M

Cash & ST Invst.

CA$200.42K

Total Debt

CA$169.56K

Avicanna Performance Analysis

Avicanna annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CAD 4,047,88123.8%
20232023-12-31CAD 16,791,483314.8%
20242024-12-31CAD 25,459,21551.6%
20252025-12-31CAD 25,478,6950.1%
Avicanna sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-303.9%
Q42025-12-313.2%
Q12026-03-311.2%
Q22026-06-30-15.6%
Avicanna annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CAD -0.23-44.2%
20232023-12-31CAD -0.09-59.0%
20242024-12-31CAD -0.04-57.1%
20252025-12-31CAD -0.02-37.8%
Avicanna sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-84.1%
Q42025-12-3132.8%
Q12026-03-3137.2%
Q22026-06-30-65.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CA$5.64M

-8.4%

Gross Profit

CA$2.99M

-4.3%

Gross Margin

53.11%

N/A

Market Cap

CA$14.78MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

CA$131.98K

N/A

Employees

112

N/A

Net Income

-CA$1.02M

-45.7%

EBITDA

-CA$917.13K

-81.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CA$200.42K

-3.5%

Total Debt

CA$169.56K

+357.1%

Accounts Receivable

CA$4.09M

+47.4%

Inventory

CA$4.61M

+5.1%

Long Term Debt

CA$0.00

N/A

Short Term Debt

CA$169.56K

+357.1%

Return on Assets

-16.21%

N/A

Return on Invested Capital

-25.76%

N/A

Free Cash Flow

-CA$1.33M

-516.9%

Operating Cash Flow

-CA$1.16M

-796.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LABS.TOMediPharm Labs Corp.
CA$0.07+0.00%
RVX.TOResverlogix Corp.
CA$0.09+0.00%
ROMJ.VRubicon Organics Inc.
CA$0.48+5.49%
CWEB.TOCharlotte's Web Holdings, Inc.
CA$0.45+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$152.71-1.36%
NVDANvidia
$222.27+1.34%
AGNCAGNC Investment Corp.
$9.87-0.40%
INTCIntel
$108.60-0.18%

Questions About AVCN

What is the current price of Avicanna?

Avicanna is trading at CA$0.11 per share.

What is the 52-week range for Avicanna?

Over the past 52 weeks, Avicanna has traded between CA$0.10 and CA$0.30.

How much debt does Avicanna have?

As of the most recent reporting period, Avicanna reported total debt of CA$169.56K.

How much cash does Avicanna have on hand?

Avicanna reported CA$200.42K in cash and cash equivalents in its most recent financial results.

What is Avicanna’s dividend yield?

Avicanna does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services